This edition covers:
- How GLP-1s impact brain circuitry and hunger cues
- The impact of reduced food noise on cognitive and emotional bandwidth
- How between-visit care supports neuroplasticity
GLP-1s were designed as a metabolic intervention, first for glycemic control in type 2 diabetes and now widely for weight management. But if you listen to people on these medications, and look at the emerging neuroscience, it’s clear they’re doing something much bigger than suppressing appetite. Evidence suggests that they may be changing how the brain assigns value to rewards, which has a significant and complex impact on health behavior. These medications do something that years of effort alone often couldn’t: reducing not just hunger, but the desire to pursue food as a reward.
Researchers scanning the brains of adolescents on GLP-1 treatment have reported changes in connectivity networks that govern what we notice and care about, not just what we crave. Clinicians are seeing the same thing play out in practice: GLP-1s don’t just act in the gut, they quiet parts of the brain that usually light up for food and other tempting cues.
How GLP-1s Impact Brain Circuitry and Hunger Cues
GLP-1 medications act on brain circuits that decide how hungry we feel, how strong our cravings are, and how rewarding certain foods seem. You can think of eating as being guided by two “voices:” one from the gut and energy system that signals hunger and fullness, and one from reward circuits that make certain foods feel especially exciting and hard to resist.
GLP-1 is a naturally occurring gut hormone that also talks to the brain, traveling along the gut–brain axis and acting on GLP–1–sensitive brain cells; the amount of medication-level doses present in the body can directly influence the circuits that control both hunger and cravings. Brain-imaging studies suggest GLP-1 medications can dial down how strongly the brain reacts to high-calorie food cues, so those foods feel less compelling rather than simply making people “less hungry” in general.
In the real world, patients often describe this as a dramatic reduction in “food noise,” i.e. the constant mental chatter about what to eat next, and a loosening of the grip of certain cues and habits. However, that quieting doesn’t always stop at hunger, it impacts addiction as well.
Hunger and addiction are not the same process, but they talk to each other through overlapping brain circuits. Your basic “I need fuel” hunger signals mostly run through regions like the hypothalamus and brainstem, which help the body keep energy in balance. The “I want that now” pull of pleasure and addiction leans more on the brain’s reward system, especially the mesolimbic dopamine pathway that links the ventral tegmental area (VTA) with the nucleus accumbens. That pathway helps tag certain experiences and substances as particularly rewarding and worth pursuing again.
GLP-1s reach into both systems. That’s why the same class of medications that quiet food noise is being actively explored as treatments for alcohol use disorder, nicotine dependence, and binge eating, with early trials and reviews pointing to reductions in substance use and compulsive eating for some patients. The mechanism is broader than appetite, and the implications for care are broader too.
Against that backdrop, it’s not surprising that some people on GLP-1s describe feeling a bit “flatter” or less interested in certain pleasures even as their relationship with food improves. For a subset of patients, the same pathways that turn down the urge to overeat may also dampen how rewarding other activities feel, at least for a time—another reason emotional tone and motivation deserve as much attention between visits as weight and A1c.
GLP-1s Free Up Cognitive and Emotional Space
Here is where the story gets interesting from a behavioral science perspective:
For people who have spent years managing relentless food noise, the quieting effect doesn't just change their relationship with food, it can also reduce the constant decision fatigue and emotional strain often tied to cravings and food choices. This can free up cognitive and emotional resources that were previously consumed by that internal negotiation. In a population already managing high rates of chronic disease, stress, and financial and social pressure, that freed-up mental bandwidth is not a small thing.
But quieter food noise alone is not a behavior change plan. Turning that mental space into long-term health requires learning a specific set of skills, such as:
- Recognizing genuine hunger and fullness cues
- Developing a more intentional relationship with food
- Building movement habits that feel sustainable
- Processing the emotions and shifts in self-image that come with living in a changing body
No one is born knowing how to do these things; the brain learns them over time through practice, feedback, and repetition. GLP-1s quiet the food noise and reduce reward-driven eating, and behavior change interventions and coaching help turn that quiet into new, more automatic patterns the brain can rely on long-term.
Without support, the newfound bandwidth often goes unspent or gets filled by the next available source of noise. Old eating patterns reassert themselves not because the person lacks willpower, but because the underlying habits, environments, and coping patterns were never addressed. A meta-analysis of people who stopped GLP-1 therapy without behavior change support found that, on average, they regained a meaningful share of the weight they had lost, with much of that regain happening in the first year after discontinuation.
The medication created the opening. But without support, that opening was never filled with new skills or routines, allowing old patterns to flow back in.
When people have access to coaching and structured support, that same freed bandwidth can be used to help the brain learn and reinforce these skills through practice, feedback, and repetition. The GLP‑1 quiets the food noise; the behavioral intervention helps decide what fills the silence.
Between-Visit Care Supports Neuroplasticity
In Omada’s 12‑week GLP‑1 body composition study, adults who had recently started a GLP‑1 and joined Omada’s GLP‑1 Care Track lost more total weight and saw more favorable shifts in body fat while preserving muscle than those without Omada support.
A clinical insight in JAMA Internal Medicine makes the same point from the clinic’s perspective: diet and physical activity, it argues, remain crucial when prescribing GLP-1s — especially for protecting muscle, maintaining adequate nutrition, and turning short-term weight loss into durable health gains.
Between doctor visits, Omada’s care team and digital tools can help people use the freed-up mental space to notice patterns, practice new responses, and reinforce small wins outside of the scale. Structured check-ins, tailored education, and coach messaging give the brain repeated opportunities to encode new habits around eating, movement, sleep, and coping, instead of defaulting back to old loops.
This is neuroplasticity in action: over time, those repetitions can help “rewire” more automatic pathways, so healthier choices require less effort and less willpower than they did before.
This kind of neuroplasticity can last beyond GLP-1 discontinuation when it is paired with behavior change support. In Omada’s GLP-1 program, average weight loss at one year was 18.4% for members who remained persistent on medication and 13.1% for members who discontinued a GLP-1 before one year.
Intrinsic Motivation and Behavioral Health Monitoring
Weight loss and A1c are important outcomes, and they can be very motivating, especially at the beginning of a program. But numbers alone rarely provide the daily momentum for behavior change. Health coaching that links biological change to personal meaning is what can build the kind of intrinsic motivation that GLP-1s, or any medication, can’t provide on their own.
Between-visit care should focus early on:
- Deliberate nutrition: Making every bite as nourishing as possible when total intake is lower
- Strength and movement: Protecting function, body composition and mood
- Identity: Shaping a self-story that supports healthy choices even as medication doses change
- Behavioral health monitoring: Watching for shifts in emotional health and engagement, and flagging concerning patterns
Coaches and clinicians who connect with members between visits are often the first to notice when the quiet starts to feel like numbness, or when rapid body changes may be colliding with past trauma, stigma, or relationship dynamics.
Designing a GLP‑1 Era for Body and Brain health
Tens of millions of people are on GLP‑1s today, and many more will follow. The biological effects on reward, appetite, and mental experience are real. The long‑term story is still being written.
That’s the work of between‑visit care. Omada’s role is to live in that space: to notice who is thriving and who is struggling in the quiet, to help people use this biological opportunity to build a healthier relationship with food and with their bodies, and to design support that bends both metabolic and mental health curves over the long term.
